Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway

Yasushi Iida(Jikei University School of Medicine), Aikou Okamoto(Jikei University School of Medicine)
Frontiers in Oncology
February 14, 2024
Cited by 13


Related Papers